This inventor holds 4 USPTO granted patents and 5 published patent applications. Top assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 121 
2 out of 11 Years Active: 2025-2026
Title: Innovations of Jinan Wang: Pioneering BCL-2 Selective Inhibitors
Introduction: Jinan Wang, an esteemed inventor based in Lianyungang, China, has made significant contributions to the field of pharmaceuticals through his innovative work. Holding two patents, he focuses on developing selective inhibitors for the BCL-2 protein, a key player in cancer therapies.
Latest Patents: Jinan Wang's latest patents include groundbreaking advances in the fight against cancer. The first patent, "Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor," details a novel compound designed to inhibit anti-apoptotic BCL-2-related diseases. This compound, along with its stereoisomers and pharmaceutically acceptable salts, not only demonstrates a unique preparation method but also outlines its pharmaceutical applications.
His second patent, "Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor," builds upon this foundation. It describes a compound effective at targeting BCL-2-related diseases, providing specific details about its structure, preparation, and various uses in treating cancer, enhancing the therapeutic landscape for patients.
Career Highlights: Jinan Wang is affiliated with Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a prominent player in the pharmaceutical industry, known for its commitment to innovation and research. His work within this company has allowed him to refine his inventions and contribute to the development of effective treatments.
Collaborations: Throughout his career, Jinan has collaborated with esteemed colleagues, including Fei Liu and Hongjiang Xu. These partnerships reflect a collaborative spirit that fosters innovation and accelerates the development of new therapeutic solutions.
Conclusion: Jinan Wang's contributions to medicine, particularly in the domain of BCL-2 selective inhibitors, illustrate the vital role of inventors in advancing healthcare. His patents not only showcase his inventive talents but also highlight the potential for his work to impact cancer treatment significantly. As research continues to evolve, Jinan Wang stands as a beacon of innovation in the pharmaceutical landscape.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile